1. A combination comprising a first agent which is an inhibitor of Smoothened proteins and a second agent that is an inhibitor of mTOR, wherein the first agent is 2 - [(R) -4- (6-benzyl-4,5-dimethylpyridazin-3-yl ) -2-methyl-3,4,5,6-tetrahydro-2H- [1,2 ] bipirazinil-5-yl] propan-2-ol or a pharmaceutically acceptable sol.2. A combination according to claim 1, wherein said second agent is an allosteric inhibitor of mTOR, exhibiting activity against mTORC1 complex, or ATP-competitive inhibitors of mTOR, exhibiting activity against complexes mTORC1 and mTORC2.3. A combination according to claim 1, wherein said second agent is selected from the group consisting of AY-22989, everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.4. A combination according to claim 3, wherein the second agent is everolimus.5. Use of a combination according to any one of claims 1-4 for the treatment of cancer associated with Hedgehog signaling pathway or mTOR.6. Use according to claim 5, wherein the cancer is medulloblastoma.7. Use of a combination for treating medulloblastoma, where the combination comprises a first agent which is an inhibitor of Smoothened proteins and a second agent that is an inhibitor of mTOR, wherein the first agent is [6- (cis-2,6-dimethylmorpholine-4-yl) pyridine-3 -yl] amide 2-methyl-4-trifluoromethoxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable sol.8. Use according to claim 7, wherein said second agent is an allosteric inhibitor of mTOR, exhibiting activity against mTORC1 complex, or ATP-competitive inhibitors of mTOR, exhibiting activity against complexes mTORC1 and mTORC2.9. Use according to claim 7, wherein said second agent is selected from the group consisting of AY-22989, everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.10. Use according to claim 9, wherein the second agent is a1. Комбинация, включающая первый агент, который является ингибитором белков Smoothened, и второй агент, кото
